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Abstract
Tuberous sclerosis complex (TSC) is a human genetic disorder in which loss of either TSC1 or TSC2 leads to development of
hamartoma lesions, which can progress and be life-threatening or fatal. The TSC1/TSC2 protein complex regulates the state
of activation of mTORC1. Tsc2
+/2 mice develop renal cystadenoma lesions which grow progressively. Both bortezomib and
metformin have been proposed as potential therapeutics in TSC. We examined the potential benefit of 1 month treatment
with bortezomib, and 4 month treatment with metformin in Tsc2
+/2 mice. Results were compared to vehicle treatment and
treatment with the mTORC1 inhibitor rapamycin for 1 month. We used a quantitative tumor volume measurement on
stained paraffin sections to assess the effect of these drugs. The median tumor volume per kidney was decreased by 99% in
mice treated with rapamycin (p=0.0004). In contrast, the median tumor volume per kidney was not significantly reduced for
either the bortezomib cohort or the metformin cohort. Biochemical studies confirmed that bortezomib and metformin had
their expected pharmacodynamic effects. We conclude that neither bortezomib nor metformin has significant benefit in this
native Tsc2
+/2 mouse model, which suggests limited benefit of these compounds in the treatment of TSC hamartomas and
related lesions.
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Introduction
TSC is an autosomal dominant tumor suppressor gene
syndrome in which hamartomas develop in multiple organ
systems, including the heart, brain, skin, kidneys, lymphatic
system, and lungs [1]. Although most lesions have a benign course,
several can grow progressively necessitating clinical intervention
with drug treatment and/or surgery.
TSC is due to mutations in either TSC1 or TSC2, and
progressive lesions typically show complete loss of one gene
product or the other [1]. The TSC1/TSC2 protein complex
serves a unique function in negatively regulating the amount of
GTP-RHEB in the cell, by acting as a GTPase activating protein
(GAP) for RHEB [2,3]. GTP-RHEB is an essential activator of
mTOR complex 1 (mTORC1), with downstream effects on
transcription and translation, cellular metabolism, autophagy,
ribosome biogenesis, cell size control, and cell proliferation [4,5].
mTORC1 is constitutively activated in cells lacking either TSC1
or TSC2 and in hamartomas from TSC patients [6].
Rapamycin (sirolimus) and related drugs (everolimus), which
bind to and inhibit mTORC1 through FKBP12, have shown
clinical activity for treatment of several manifestations of TSC,
including renal angiomyolipomas, pulmonary lymphangioleio-
myomatosis, and brain subependymal giant cell astrocytomas [7–
10]. However, rapamycin does not cause complete regression of
disease in most instances, and cessation of treatment can lead to
regrowth of hamartoma lesions [8]. Rapamycin is also an
immunosuppressant, and although it is well tolerated in most
patients during follow-up of up to 5 years, there is concern that
long-term treatment may lead to significant cumulative or
otherwise unexpected toxicity. A fraction of patients also do not
tolerate the drug, mainly due to oral mucositis [7–10].
Other therapeutic approaches to control the growth of TSC-
related tumors have been suggested. Loss of the TSC protein
complex and activation of mTORC1 leads to elevated and
uncontrolled protein synthesis, which leads to endoplasmic
reticulum (ER) stress and induction of the unfolded protein
response (UPR) [11]. One potential therapeutic approach
therefore is to exacerbate ER stress in tumor cells lacking the
TSC genes by treatment with proteasome inhibitors such as
bortezomib [12]. Bortezomib is approved for clinical use in
multiple myeloma [13], and is thought to cause the selective death
of myeloma cells through induction of apoptosis. A second
alternative therapeutic approach is the use of AMPK activators.
AMPK inhibits the activation of mTORC1 through both
activating phosphorylation of TSC2 [14,15], and inhibitory
phosphorylation of mTORC1 on the core component Raptor
[16]. In addition, compounds which induce ATP depletion and
energy stress can also selectively kill cells lacking TSC1 or TSC2
[17]. Several AMPK inhibitors are available for clinical investi-
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AMPK by elevating cellular AMP levels [18], and is recom-
mended as first line therapy for adult onset diabetes mellitus, to
reduce serum glucose and Hemoglobin A1c levels [19]. It is
generally well tolerated and has been taken by some patients for
more than a decade. In addition, metformin has been shown to
prevent tumorigenesis in mouse model studies [20,21].
Tsc2
+/2 mice develop renal cystadenomas that progressively
develop as the mouse ages, with increasing cellular atypia in some
lesions that progress to renal cell carcinoma [22]. The Tsc2
+/2
renal cystadenoma phenotype is most pronounced in the A/J
strain of mice (unpublished data). Here we used Tsc2
+/2 A/J mice
to examine the potential benefit of bortezomib and metformin
treatment for renal cystadenomas, in comparison to rapamycin
and vehicle controls.
Results
Cohorts of A/J strain Tsc2
+/2 mice were treated with one of 5
regimens: 1) rapamycin given at 6 mg/kg IP three days per week
(n=9); 2) vehicle given on the same schedule (n=5); 3) bortezomib
given at 0.8 mg/kg SC two days per week (n=8); 4) metformin
given in 5% sucrose drinking water at 300 mg/kg per day (n=10);
and 5) 5% sucrose drinking water (n=8). Cohorts were chosen to
be balanced by sex; the first three cohorts were treated
concurrently, as were the last two cohorts. Since rapamcyin has
previously been shown to cause a marked reduction in tumor
volume in Tsc2
+/2 mice, it was given for one month only, as we
have done previously [23]. Bortezomib was also given for one
month only, as it may be considered a relatively active therapeutic
with potential toxicity and side-effects, such that long-term
administration in patients would not be desirable. The dosage
used has been established as an MTD in previous studies in
xenograft models, and is effective for sensitive tumors [12]. In
contrast, since metformin is taken by many patients for many
years, it was given to these mice for a period of 4 months,
modeling a long-term preventive mode of treatment. The dosage
of metformin was taken from a previous study in which this dose
was effective in prevention of tumors in a combined LKB1-PTEN
mouse model [21]. All mice were sacrificed at 5 months of age.
Mice received rapamycin and bortezomib from age 4 to 5 months;
and received metformin from age 1 month to age 5 months. Note
that one mouse treated with bortezomib died unexpectedly during
treatment. Otherwise there was no apparent toxicity or difference
in weight among any of the cohorts (Table 1).
Among the five treatment cohorts, the only cohort showing a
significant difference in tumor extent as assessed by gross
observation was the rapamycin treatment cohort (Figure 1A).
Gross tumor extent was significantly reduced in the rapamycin
cohort in comparison with IP vehicle (p=0.0012, Mann Whitney
test), as well as in pairwise comparison with every other treatment
cohort (p#0.01). All comparisons among other treatment cohorts
were not significant (p.0.2 for each other pairwise comparison).
Similarly, quantitative scoring of microscopic tumor volume per
kidney showed that the rapamycin-treated mice had a markedly
reduced tumor volume in comparison with every other treatment
group, with p=0.0004 in comparison to the IP vehicle cohort, and
p#0.001 in comparison to the other 3 cohorts (Figure 1B). Indeed,
visualization of tumor volume on a log scale (Figure 1C)
illuminated the ,100-fold difference in median tumor volume in
the rapamycin-treated cohort in comparison to all other cohorts
(median tumor volume 0.93 mm2 for IP vehicle, and 0.011 mm2
for rapamycin). This figure also illustrates the marked variability in
the extent of tumor formation in this pure strain genetic model,
likely reflecting the important effect of stochastic variation in
second hit genetic events important in tumor development. In
contrast, by quantitative microscopic assessment, there were only
marginal differences among the four other cohorts. There was a
trend towards a difference in comparison of both the bortezomib
cohort and the metformin cohort with the sucrose cohort,
p=0.054 and 0.084 respectively. However, comparison with the
IP vehicle group showed no significant difference, p$0.16.
Combining the IP vehicle and sucrose cohorts, and repeating
the comparisons gave p values of 0.041 and 0.083 for the
comparisons of the bortezomib and metformin cohorts with the
combined vehicle cohort respectively. Microscopic review of renal
cystadenoma histology demonstrated that there was no apparent
change in the appearance of tumors from the bortezomib and
metformin cohorts in comparison to controls (Figure 2). In
contrast, the rapamycin-treated mouse tumors were almost
entirely cystic, and the cyst-lining cells had a flattened appearance
in comparison to tumor cells from the other four cohorts (Figure 2),
as has been noted previously in rapamycin or RAD001 treated
Tsc2
+/2 mice [23].
To confirm that these drugs were hitting their intended
molecular targets in the kidneys of these mice, two studies were
performed. Separate sets of Tsc2
+2 AJ strain mice were treated
with the drugs for one week, and sacrificed for immunoblot
analysis of kidney tissue lysates. Antibodies used in this assay were
designed to examine the activity of mTORC1 (phospho-S6-S235-
236, pS6-S235; pS6-S240/S244) [6]; the activity of AMPK
(phospho-ACC-S79 and pRaptor-S792) [24]; and proteasome
inhibition (GRP78/BiP, phospho-IkBa-S32/36) [25]. Levels of
pS6-S235/S236 and pS6-S240/S244 were markedly reduced in
kidney lysates from mice treated with rapamycin, and were not
changed in mice treated with the other agents (Figure 3A).
Similarly, mice treated with metformin showed an increase in both
pACC-S79 (Figure 3A) and pRaptor-S792 (Figure 3B) levels.
Bortezomib treatment markedly induced GRP78, consistent with
this drug acting as a potent activator of the unfolded protein
response (UPR) (Figure 3B). Bortezomib treatment also led to an
Table 1. Body weight of mice on treatment.
Treatment Age
Average
weight
Standard
deviation Median
Number
of mice
IP vehicle 4 m 26.2 1.91 25.5 5
IP vehicle 5 m 25.2 1.91 24.3 5
Rapamycin 4 m 25.2 1.38 25.0 9
Rapamycin 5 m 25.1 1.15 25.3 9
Bortezomib 4 m 24.8 1.51 24.6 7
Bortezomib 5 m 23.4 1.59 23.3 7
Sucrose 1 m 18.3 2.28 18.5 8
Sucrose 2 m 21.3 1.95 21.3 8
Sucrose 3 m 23.7 1.66 23.7 8
Sucrose 4 m 25.6 2.16 25.6 8
Sucrose 5 m 25.2 2.61 25.2 8
Metformin 1 m 16.7 1.10 16.8 10
Metformin 2 m 21.4 2.59 21.2 10
Metformin 3 m 23.9 3.41 23.3 10
Metformin 4 m 25.1 2.37 24.7 10
Metformin 5 m 26.3 2.47 26.3 10
doi:10.1371/journal.pone.0031900.t001
Metformin and Bortezomib in a Mouse Model of TSC
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metformin treatment (Figure 3B). pACC-S72 levels were some-
what variable in rapamycin- and bortezomib-treated mice, but
were much less than what was seen with metformin treatment
(Figure 3A). Immunohistochemistry analysis performed on tumors
from Tsc2
+/2 mice treated with these agents for one week
confirmed these findings (Figure 4). There was a complete absence
of pS6-S235/236 staining in rapamycin-treated mouse tumors, in
contrast to mice treated with the other drugs. Metformin led to an
increase in pACC-S79 levels. Bortezomib led to an increase in
both pIkBa-S32/36 and GRP78 levels. Apoptosis was not
appreciated in these mouse tumors after one week of any
treatment by TUNEL staining (Figure 4).
Discussion
In this study, we have confirmed the dramatic therapeutic
effectiveness of rapamycin treatment of Tsc2
+/2 mice for the
renal cystadenoma lesions which are known to develop through a
2-hit mechanism of complete loss of Tsc2 expression [22].
Multiple previous studies have demonstrated this response to
rapamycin and its analogs [23,26,27]. However, it was important
to perform this positive control concurrently with our test
compounds.
In contrast, we saw little or no therapeutic benefit in Tsc2
+/2
mice in response to treatment with bortezomib. There was
marginal evidence of benefit when comparing the bortezomib
cohort to the combined IP vehicle and sucrose control cohorts
(p=0.041). This agent is currently FDA-approved for treatment
of multiple myeloma [13], and acts by inhibiting the proteasome
to enhance ER stress in malignant plasma cells that produce
large amounts of immunoglobulin, leading to inhibition of
proliferation and apoptotic cell death [28]. This effect was not
seen in the mice treated in our study, as indeed, there was no
appreciation of cell size increase in mice treated for either one
week or one month of bortezomib (Figures 2 and 4). However, our
studies show that the UPR pathway was enhanced in the normal
tissues and tumor lesions in these mice, as manifest by increased
levels of GRP78/BiP, a known target of ATF6 [29]. Therefore,
it appears that the level of increase in ER stress and UPR
was insufficient to induce cell death in this particular Tsc2+2
genetic model.
Similarly, metformin also failed to demonstrate therapeutic
benefit in this model. Mice were treated with a conventional,
relatively high dose of drug [21], and our analyses indicated that
there was induction of AMPK activation in response to treatment
(Figures 3 and 4). Metformin was chosen for use in this study
because of its widespread use in the treatment of diabetes mellitus
Figure 1. Macroscopic and microscopic kidney tumor scores for Tsc2
+/2 mice treated with five different treatment regimens. Scores
are shown for each kidney available from each mouse in these cohorts. A. Macroscopic kidney tumor scores. B–C. Microscopic kidney tumor volume is
shown twice, on a linear y axis scale (B) and on a logarithmic y axis scale (C). For B and C, the number of mice and kidneys examined were: 5 and 7, 9
and 15, 7 and 12, 8 and 14, and 10 and 18, respectively, for IP vehicle, rapamycin, bortezomib, sucrose, and metformin cohorts, respectively.
doi:10.1371/journal.pone.0031900.g001
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at a time, important considerations for the concept of long-term
preventive treatment. As noted earlier, metformin activation of
AMPK leads to phosphorylation and activation of TSC2 [14,15].
AMPK also phosphorylates Raptor to attenuate mTORC1
activity [16]. Metformin treatment has been used to reduce tumor
Figure 2. Renal cystadenoma histology in the treated mice. Representative tumor images are shown for each treatment cohort, selected from
the kidneys with the largest tumor volume for each. Three cystadenoma each are shown at 1006, with a portion of the tumor indicated by the frame
shown at 4006(below). Cystadenomas from control mice are shown in the first column, two from IP vehicle treated mice, and one from a sucrose
treated mouse. Note the cystic nature of the tumors from the rapamycin-treated mice, as well as the flattened, thin nature of the cyst-lining cells, in
contrast to cystadenomas from all other mice. Arrows point to prominent enlarged but viable cells in the bortezomib-treated mice.
doi:10.1371/journal.pone.0031900.g002
Metformin and Bortezomib in a Mouse Model of TSC
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fl/+ Pten
+/2 mice [21], and in tobacco
carcinogen-induced lung tumorigenesis in A/J strain of mice, the
same strain used here [20]. However, it is notable that the
reduction in tumor severity was modest through statistically
significant in both of these studies, and IP administration at a high
dose was required to achieve the greatest benefit in the lung cancer
model [20]. We suspect that the complete absence of Tsc2 in these
Tsc2
+/2 cystadenoma lesions leads to strong activation of
mTORC1 due to constitutive high levels of RHEB-GTP, which
makes these lesions resistant to the lesser effect of Raptor
phosphorylation. This is reflected in a lack of decrease in
mTORC1 signaling in the lesions following metformin treatment,
with persistent strong pS6-S235/236 expression, in contrast to the
effects seen with rapamycin treatment (Figure 3, 4). However, it is
notable that part of the therapeutic benefit of metformin in
previous tumor studies may relate to effects on circulating insulin
and insulin-like growth factor levels, as well as energy stress
[20,30].
The current studies are important in indicating the likely limited
therapeutic benefit of both bortezomib and metformin for
treatment of TSC and related disorders, including renal
angiomyolipoma and pulmonary lymphangioleiomyomatosis
(LAM). It is possible that a more potent AMPK activator such
as AICAR or phenformin would be more effective at inhibition of
both mTORC1 signaling and growth in Tsc2
+/2 cystadenoma
lesions since they are also more effective in in vitro studies on
TSC2-deficient fibroblasts [16]. However, those agents are not
readily available for clinical testing in the US population. Indeed,
development of more potent bioavailable AMPK activators for
clinical use would be very helpful for further analysis of this
potential therapeutic approach. Although there is a continuing
need for therapeutic development and refinement for treatment of
TSC and related disorders, our data suggests that metformin and
bortezomib will not have major benefit.
Materials and Methods
Ethics statement
All procedures were carried out in accordance with the Guide
for the Humane Use and Care of Laboratory Animals, and the
study was approved by the Animal Care and Use Committee of
Children’s Hospital, Boston.
Mouse procedures
Tsc2
+/2 mice, originally generated in this laboratory [22], were
serially crossed with A/J mice for over 5 generations. These pure
strain mice were used in all experiments.
Standard histology and tumor assessment
Mouse kidneys were removed rapidly after euthanasia, and were
fixed overnight in 10% formalin. Gross scoring of kidney tumor
lesions was performed by a single observer (NA). The gross tumor
score for each kidney was determined as a summed score for all
lesions in a kidney, scoring each individual tumor grossly as
follows: 1 for tumors ,1 mm; 2 for 1 to 1.5 mm; 5 for 1.5 to
2 mm; 10 for .2 mm [23]. Kidneys were then prepared for
histologic evaluation in stereotypical fashion by cutting the kidney
into sections at 1 mm intervals throughout its length.
Microscopic kidney tumor scores were determined in a semi-
quantitative fashion by a single blinded observer (IM). The set of
1 mm interval sections were prepared as H&E-stained 8 micro-
meter sections. Each tumor or cyst identified was measured to
determine its length and width in two dimensions, as well as the
percent of the lumen filled by tumor (this was 0% for a simple cyst,
and 100% for a completely filled, solid adenoma). These
measurements were converted into a measurement of tumor
volume per lesion using the following formula. Tumor volume=
maximum(tumor percent, 5)/100 * 3.14159/6 * 1.64 * (tumor
length * tumor width)**1.5 [31]. The total tumor volume per
kidney was then equal to sum of the tumor volume of each lesion
identified. Comparisons between sets of mice for tumor measure-
ments were made using the non-parametric Mann Whitney test in
Prism (GraphPad Software, Inc., v4.0a).
Immunoblotting
Mouse kidneys were harvested for immunoblotting by rapid
post-mortem freezing in liquid nitrogen and were stored at 280uC
until further use. Lysates from kidney samples were prepared by
standard methods [23]. Protein concentrations were determined
using the Bradford Assay, and equal amounts were separated by
electrophoresis on pre-cast 4–12% Bis-Tris gels (Invitrogen) and
transferred onto PVDF membranes. The membranes were
blocked with 5% nonfat dry milk in TBS-T (Tris Buffered
Saline-10% Triton-X) for one hour at room temperature. Primary
antibodies were diluted in 5% bovine standard albumin (BSA) in
PBS, 0.1% Tween20 (pH 7.4) solution and were applied to the
membranes for overnight incubation at 4uC in a wet chamber.
Antibodies used for Western blotting were as follows: pACC (S79,
Millipore,Temecula, CA); Akt (Santa Cruz Biotechnology, Santa
Cruz, CA); GRP78/BiP (Enzo, Farmingdale, NY; formerly
Stressgen); and pIkBa (S32/36), pS6 (S240/244), pS6 (S235/
236), total S6 and pRaptor (S792) (all from Cell Signaling
Technology, Bedford, MA).
After extensive washing, HRP-conjugated secondary antibodies
(Santa Cruz) were applied for 1 hour at room temperature.
SuperSignal West Pico (ThermoScientific) chemiluminescence
reagents were used to detect antibody binding. Images were
collected digitally using the Syngene G-box iChemi XT GeneSnap
Program (Version 7.09.06).
Figure 3. Immunoblot analysis of kidney lysates to examine
therapeutic specificity. Tsc2
+2 A/J strain mice were treated with
vehicle, rapamycin, bortezomib or metformin for 1 week, and kidney
lysates were prepared for immunoblot analysis. A) Blot strips were
incubated with the antibodies against pACC-S79, AKT, pS6-S235/236,
pS6-S240/244 and S6. B) Blot strips incubated with antibodies against
pRaptor-S792, GRP78 and AKT.
doi:10.1371/journal.pone.0031900.g003
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Eight micrometer paraffin sections were deparaffinized with a
xylene and alcohol series, treated with Target Retrieval Solution
pH 6.1 (Dako, Carpinteria, CA), blocked with 3% H2O2 in
methanol, and then put in 5% normal goat serum in 0.1% Triton
X in PBS. Sections were incubated with primary antibodies
overnight at 4uC, washed, and incubated with secondary antibody
conjugated with horseradish peroxidase (HRP). AEC (3-amino-9-
ethylcarbazole, Envision+System Dako) was then applied to
generate a color reaction. Slides were then counterstained with
hematoxylin (Dako). Antibodies used for staining were: pACC-S79
(1:100, Millipore #07-303); anti-pIkBa-S32/36 (1:100, Cell
Signaling, #9246); anti-pS6-S235/236 (1:1000, Cell Signaling,
#2211), GRP78 BiP (1:3000, Abcam, #21685).Apoptosis was
Figure 4. Immunohistochemistry (IHC) analysis of therapeutic effects. Tsc2
+/2 A/J strain mice of ages 9–10 months were treated with drugs
for 1 week, and kidneys prepared for histology. Sections were prepared and stained using pS6-S235/236 (red), pACC-S79 (red), pIkBa-S32/34 (red) and
GRP78 (red) antibodies. The bottom panel shows apoptosis assessed by TUNEL method. Representative sections are shown. All images shown are
taken at 1006magnification. Insets show portions of the tumor at higher magnification (4006).
doi:10.1371/journal.pone.0031900.g004
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Peroxidase In Situ Apoptosis Detection Kit (Millipore, formerly
Chemicon) by the TUNEL method and counterstained with
methylene green (Sigma).
Drug handling and administration
Metformin was purchased from Sigma-Aldrich (St. Louis, MO;
D15,095-9), and was dissolved in 5% sucrose and provided to the
mice in their drinking water, such that the mice received 300 mg/
kg daily. Mice drank 3–15 ml/day, and the concentration was
adjusted every other day according to their consumption and body
weight, to achieve the desired daily dose. A sucrose control group
of mice received 5% sucrose as drinking water without additive.
Both the metformin and the sucrose controls received treatment
for 4 months, from age 1 month to age 5 months.
Rapamycin was purchased from LC laboratories (Woburn,
MA). A 20 mg/ml stock was made using ethanol, and mixed daily
for injection with sterile vehicle (0.25% PEG-200, 0.25% Tween-
80). Mice were treated with rapamycin by intraperitoneal (IP)
injection at 6 mg/kg three times per week for one month. Control
mice received the vehicle solution IP on the same schedule.
Bortezomib was also purchased from LC laboratories. A 25 mg/
ml stock was made using DMSO or PBS, and was diluted daily
with sterile PBS. Mice were treated with bortezomib at 0.8 mg/kg
subcutaneously two times per week (three days apart) for one
month [12].
For short term treatment studies, 2 Tsc2
+2 AJ strain mice of age
9–10 months each were treated with rapamycin, bortezomib,
metformin, or sucrose water in the same doses as above for a
period of one week only. They were then sacrificed for rapid
collection of kidneys; one half of one kidney was rapidly frozen for
immunoblot analysis, the other half lightly fixed and prepared in
30% sucrose for frozen sections for Apoptag analysis. The other
kidney was fixed and used for immunohistorchemistry.
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